Depression is recognized as a common mental disorder. It is estimated that 5% of adults, or 350 million people around the world, suffer from this disorder. This problem is the subject of many discussions and investigations in the. Depression is one of the priority conditions covered by WHO’s Mental Health Gap Action Programme (mhGAP). In order to draw people’s attention to the problem the International Depression Awareness Day.
Nowadays, both pharmacological and non-pharmacological options are used to treat the depression. Most often a patient is offered either pharmacological or the combined treatment consisting of antidepressant medication and psychotherapy, which really works, but, unfortunately, not for everyone. If the patient does not respond to medication or can not tolerate the side effects of medication, rTMS therapy becomes an alternative. According to the results of the clinical trials, the number of responders to rTMS therapy in antidepressant treatment-resistant patients is about 50%. Also, transcranial noninvasive stimulation with direct low current (up to 2 mA) has therapeutic effect in the treatment of different disorders including major depressive disorder.
Neurosoft is developing and producing systems for transcranial magnetic stimulation and transсranial direct current stimulation:
- Neuro-MSX transcranial magnetic stimulator of a new generation
- Neuro-MS/D transcranial magnetic stimulator
- Neurostim transcranial electrical stimulator
Neurosoft creates the flagship solutions to become the popular choice for the medical practice worldwide.